Physician

Psychiatry

Dr. Carlos A. Zarate Jr., MD

Doctor Carlos A. Zarate Jr., MD is an expert in the field of Psychiatry. Doctor Carlos A. Zarate Jr., MD is a published doctor and has 77 publications published. The lastest was: 'THERAPEUTIC MODULATION OF GLUTAMATE RECEPTORS IN MAJOR DEPRESSIVE DISORDER.'

Publications

THERAPEUTIC MODULATION OF GLUTAMATE RECEPTORS IN MAJOR DEPRESSIVE DISORDER.
A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.
A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for...
Pre-treatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine.
Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.
Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression.
The relationship between glucose metabolism, resting-state fMRI BOLD signal, and GABAA-binding potential: a preliminary study in healthy subjects and those with tempor...
Neural response during explicit and implicit face processing varies developmentally in bipolar disorder.
Riluzole likely lacks antidepressant efficacy in ketamine non-responders.
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
What is hydroxynorketamine and what can it bring to neurotherapeutics?
Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety.
Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression.
Ketamine's Antidepressant Efficacy is Extended for at Least Four Weeks in Subjects with a Family History of an Alcohol Use Disorder.
Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder.
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Existing and novel biological therapeutics in suicide prevention.
Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt.
Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.
Clinical predictors of ketamine response in treatment-resistant major depression.
Do the dissociative side effects of ketamine mediate its antidepressant effects?
A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial ne...
Cerebrospinal Fluid Monocyte Chemoattractant Protein-1 in Alcoholics: Support for a Neuroinflammatory Model of Chronic Alcoholism.
Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram.
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
12-Week Placebo-Controlled Trial of Add-on Riluzole in the Treatment of Childhood-Onset Obsessive Compulsive Disorder.
DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS.
Oxidative stress in early stage Bipolar Disorder and the association with response to lithium.
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression.
Independence of familial transmission of mania and depression: results of the NIMH family study of affective spectrum disorders.
Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
Glial abnormalities in substance use disorders and depression: Does shared glutamatergic dysfunction contribute to comorbidity?
Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach.
Reduced thalamic volumes in major depressive disorder.
Ketamine, sleep, and depression: current status and new questions.
Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects.
Fronto-limbic-striatal dysfunction in pediatric and adult patients with bipolar disorder: impact of face emotion and attentional demands.
A developmental study on the neural circuitry mediating response flexibility in bipolar disorder.
New paradigms for treatment-resistant depression.
NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER.
New insights into the neurobiology, diagnosis, and treatment of mood disorders.
Rapid antidepressant effects: moving right along.
Abnormal fusiform activation during emotional-face encoding assessed with functional magnetic resonance imaging.
Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study.
Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: A double-blind, randomized pilot study.
Defining anxious depression: a review of the literature.
NEUROBIOLOGY OF ANXIOUS DEPRESSION: A REVIEW.
Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.
Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder.
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression.
Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder.
Human Biomarkers of Rapid Antidepressant Effects.
Early improvement with lithium in classic mania and its association with later response.
A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression.
Antidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review.
Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in ÃÂ±7 nicotinic acetylcholine receptors.
Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.
Automated subcortical segmentation using FIRST: Test-retest reliability, interscanner reliability, and comparison to manual segmentation.
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients.
Association Between Subcortical Volumes and Verbal Memory in Unmedicated Depressed Patients and Healthy Controls.
Downregulation of Brain Phosphodiesterase Type IV Measured with (11)C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder.
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression.
Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression.
Neural correlates of suicidal ideation and its reduction in depression.
Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action.
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Pharmacologic treatment of dimensional anxious depression: a review.
SHAPS-C: the Snaith-Hamilton pleasure scale modified for clinician administration.
Image-derived input function derived from a supervised clustering algorithm: methodology and validation in a clinical protocol using [(11)c](R)-rolipram.
Catecholamine depletion in first-degree relatives of individuals with mood disorders: An [(18)F]fluorodeoxyglucose positron emission tomography study.
Major depression is not associated with blunting of aversive responses; evidence for enhanced anxious anticipation.

Doctors Specialties

Psychiatry

Accepted Insurances

PHCS Network PPO

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Alyssa A. Soumoff, MD
	Dr. Lauren R. Hodas, MD This Doctor is OpenDoctor Recommended.
	Dr. Monroe Pray Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Robert T. Lewit, MD This Doctor is OpenDoctor Recommended.
	Dr. Sara E. Greenwald, MD This Doctor is OpenDoctor Recommended.
	Dr. Iman O. Hypolite, MD This Doctor is OpenDoctor Recommended.
	Dr. Nancy M. Diazgranados, MD This Doctor is OpenDoctor Recommended.